News stories about BIO-TECHNE (NASDAQ:TECH) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BIO-TECHNE earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.184647465234 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several brokerages have commented on TECH. Deutsche Bank set a $163.00 price objective on shares of BIO-TECHNE and gave the stock a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research upgraded shares of BIO-TECHNE from a “hold” rating to a “buy” rating and set a $158.00 price target on the stock in a research note on Saturday, January 20th. Robert W. Baird reiterated a “buy” rating and set a $154.00 price target on shares of BIO-TECHNE in a research note on Thursday, January 18th. Craig Hallum reiterated a “buy” rating and set a $160.00 price target (up previously from $140.00) on shares of BIO-TECHNE in a research note on Wednesday, February 7th. Finally, BidaskClub upgraded shares of BIO-TECHNE from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. BIO-TECHNE currently has a consensus rating of “Buy” and a consensus target price of $148.60.
BIO-TECHNE (NASDAQ:TECH) opened at $146.36 on Monday. The firm has a market cap of $5,484.69, a price-to-earnings ratio of 47.99, a PEG ratio of 2.81 and a beta of 0.75. BIO-TECHNE has a one year low of $98.22 and a one year high of $147.05. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.49 and a current ratio of 3.10.
The firm also recently declared a quarterly dividend, which was paid on Friday, March 2nd. Stockholders of record on Friday, February 16th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend was Thursday, February 15th. BIO-TECHNE’s dividend payout ratio is presently 41.97%.
In related news, Director Charles A. Dinarello sold 5,000 shares of BIO-TECHNE stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $136.06, for a total transaction of $680,300.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.40% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://sportsperspectives.com/2018/03/12/bio-techne-tech-earns-news-impact-score-of-0-17.html.
BIO-TECHNE Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.